Result: 61 - 80 of 96
DRAMP IDNAMEDescriptionMedical_useStage of developmentCompany
DRAMP18173Pediocin PA-1 (Bacteriocin)Pediococcus acidilactici UL5Gastrointestinal tract infections; Stomach and intestine infections (Murine model; In-vivo)PreclinicalUnknown
DRAMP18174Nisin A (Type A lantibiotic)Lactococcus lactis subspUrogenital tract infections; Spermicidal activity (Rabbit model; In-vivo) PreclinicalUnknown
DRAMP18175Bac8cSynthetic derivative of bactenecin from bovine neutrophilsStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP18176Temporin10aFrog (Rana ornativentris) skinStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP18177Syphaxin(SPX1-22)Frog (Leptodactylus syphax) skinStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP18178IDR-1IDR-1 is a 13-amino acid peptide derived from bovine neutrophils that shows antimicrobial activity against MRSA, VRE, and other Gram-positive and Gram-negative pathogens.Prevention of infections in the immune compromisedPhase IUnknown
DRAMP18179IDR-1002Derivative of bactenecin from bovine neutrophilsStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP18180Buforin IIAsian Toad (Bufo bufo gargarizans) stomachStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP20773Dusquetide(SGX942)Dusquetide is a synthetic, 5-amino acid peptide and Innate Defense Regulator (IDR), with immunomodulating, anti-inflammatory, anti-infective and anti-mucositis activities. Upon intravenous administration, dusquetide binds to the ZZ domain of sequestosome-1, also called p62, and activates regulatory signaling transduction pathways involved in the modulation of the innate immune system, such as those mediated by mitogen-activated protein kinase (MAPK) p38 and CCAAT-enhancer-binding protein. This agent promotes monocyte and macrophage recruitment to, and accelerates healing in damaged and infected tissue; it suppresses inflammation through the regulation of the expression of multiple cytokines. This agent may prevent or decrease chemo- or radiotherapy-induced mucositis as well as other types of infection. p62, an intracellular adaptor protein that functions downstream of certain signaling receptors, plays a key role in the activation of the innate immune system.Treatment for oral complications caused by radiation therapy for head and neck cancer.Phase III Soligenix
DRAMP20760C16G2a synthetic AMPTreatment of Adult and Adolescent Dental SubjectsPhase IILantibio
DRAMP18181DP178 (T20, Enfuvirtide & Fuzeon)Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.Human Immunodeficiency Virus (HIV) Infections; AIDSProved by FDATrimeris
DRAMP18182Sifuvirtide (SFT)designed based on the 3D structure of the HIV-1 gp41 fusogenic core conformationHIV fusion inhibitor;AIDSPhase II Unknown
DRAMP18183SB006 (M6)tetra-branched multimeric form of the linear sequenceGram-negative infectionsPreclinicalSpiderBiotech
DRAMP20761LTX-109LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis. Uncomplicated Gram positive skin infections, impetigo,and nasal colonization with S. aureusPhase I/IILytix Biopharma AS
DRAMP20774Murepavadin (POL7080)synthetic by amino acid substitution of protegrin I.Treatment of nosocomial pneumonia and ventilator-associated bacterial pneumonia (VABP)Phase III(suspended, adverse events)Polyphor Ltd.
DRAMP18160Omiganan (MBI-226/MX-226/CLS001)Omiganan (MBI-226), an analogue of indolicidin, has been proven to be capable of significantly reducing catheter colonization and microbiologically confirmed tunnel infections during catheterizationRosacea, Acne vulgaris (II), Genital warts (II)Phase III(catheter-related infections,Failure), Phase III(rosacea, completed), Phase II(atopic dermatitis (AD), usual type vulval intraepithelial neoplasia (uVIN), external genital warts, and acne vulgaris, completed), Phase III(facial seborrheic dermatitis, recruiting)Maruho Co., Ltd(developing), Cutanea Life Sciences, Inc.(developing), Mallinckrodt, Micrologix Biotech(Vancouver, BC, Canada)
DRAMP28983PL-5This product is a national category 1 anti-infective innovation category in China, and has obtained PCT US and Chinese invention patent authorizations. Suitable for skin and wound infections, especially for stubborn infectious diseases caused by drug-resistant bacteria, against traditional antibiotics, "super bacteria" Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Acinetobacter baumannii containing NDM-1 gene have very strong bactericidal advantages. Its preparation antimicrobial peptide PL-5 spray is the first antimicrobial peptide variety to enter clinical research in my country, and this product has also been supported by the National Health and Family Planning Commission’s 12th and 13th Five-Year "Major New Drug Development" projects. Phase I clinical research has been completed, and Phase II clinical research is currently underway.Skin wound infectionPhase IIIbChangchun ProteLight Pharmaceutical & Biotechnology Co.
DRAMP29315BacitracinBacitracin A is a homodetic cyclic peptide consisting of (4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carboxylic acid attached head-to-tail to L-leucyl,D-glutamyl, L-lysyl, D-ornityl, L-isoleucyl, D-phenylalanyl, L-histidyl. D-aspartyl and L-asparaginyl residues coupled in sequence and cyclised by condensation of the side-chain amino group of the L-lysyl residue with the C-terminal carboxylic acid group. It is the major component of bacitracin. It has a role as an antibacterial agent and an antimicrobial agent. It is a homodetic cyclic peptide and a polypeptide. prevent wound infections, treat pneumonia and empyema in infants, and to treat skin and eye infections.In market
DRAMP29316Surotomycin(MK-4261/CB-183,315)Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the intestinal microbiota. Surotomycin, given orally, has been shown to be highly effective against both initial and relapsing hamster Clostridium difficile-associated diarrhea, with a potency similar to vancomycin. Surotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection.Treatment of Diarrhea and Clostridium Difficile InfectionPhase IIICubist Pharmaceuticals Inc./Merck & Co. Inc.
DRAMP29317Colistin(polymyxin-E)Colistin is a polymyxin antibiotic used to treat bacterial infections caused by susceptible Gram negative bacteria.Treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.In market
Sign in     login

Forgot your password?